Aardvark Therapeutics, Inc.

Aardvark Therapeutics reported a net loss of $(14.39) million for Q2 2026 and $(35.98) million for the six months ended June 30, 2026, an increase from the prior year. The company's cash and cash equivalents increased to $73.85 million, while total assets decreased to $81.46 million. Aardvark believes its current capital is sufficient for at least one year and has established an At-The-Market (ATM) facility for up to $150 million to raise additional funds.

Aardvark Therapeutics reported its second quarter 2026 financial results and significant business updates. The company terminated its Phase 3 HERO and OLE trials for ARD-101 in Prader-Willi Syndrome (PWS) in June 2026, following a full clinical hold placed by the FDA on the ARD-101 program in May 2026. Aardvark is assessing unblinded data to determine next steps for the program. The company reported a net loss of $14.4 million for Q2 2026 and holds $73.9 million in cash, projecting operations into late 2027.

Aardvark Therapeutics reported its second quarter 2026 financial results and provided pipeline updates. The company is assessing unblinded data from its Phase 3 HERO and OLE trials for ARD-101 in Prader-Willi Syndrome, which were terminated in June 2026. The ARD-101 program remains under a full clinical hold by the FDA, with active discussions ongoing to resolve the issue. As of June 30, 2026, Aardvark had $73.9 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into late 2027. The company reported a net loss of $14.4 million for the second quarter of 2026.

Aardvark Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on August 14, 2026, at 9:00 a.m. Pacific Time. Shareholders as of June 18, 2026, are eligible to vote on proposals including the election of two Class I directors, the ratification of BDO USA, P.C. as the independent auditor for 2026, and the approval of repricing certain outstanding stock options under the 2017, 2025, and 2025 Inducement Equity Incentive Plans. The Board of Directors recommends voting 'FOR' all proposals.

Aardvark Therapeutics, Inc. has entered into retention bonus agreements with its Chief Financial Officer and Chief Operating Officer, Nelson Sun, and its Chief Medical Officer, Manasi Jaiman. Mr. Sun will receive a total cash retention bonus of $346,500, while Dr. Jaiman will receive $357,000. Both bonuses are contingent on their continued employment through January 1, 2027, or earlier termination without cause or resignation for good reason.

Aardvark Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101. This hold affects all ongoing clinical studies, including the Phase 3 HERO trial for Prader-Willi Syndrome and the open-label extension trial. The company is actively engaging with the FDA to resolve the hold and plans to unblind accumulated clinical data to determine the program's future. As of March 31, 2026, Aardvark reported $91.2 million in cash, cash equivalents, and short-term investments, expected to fund operations into mid-2027.

Aardvark Therapeutics reported a significant increase in net loss for Q1 2026, reaching $21.6 million, up from $9.3 million in Q1 2025, primarily due to higher research and development and general and administrative expenses. The company's cash, cash equivalents, and short-term investments totaled $91.2 million as of March 31, 2026, which is expected to sustain operations for at least one year. In March 2026, Aardvark established an ATM facility to potentially raise up to $150.0 million.

Aardvark Therapeutics announced a voluntary pause in enrollment and dosing for its ARD-101 and ARD-201 clinical programs. This decision followed unexpected reversible cardiac observations in a separate healthy volunteer trial, with further guidance expected in Q2 2026. For the first quarter ended March 31, 2026, the company reported a net loss of $21.6 million, an increase from $9.3 million in Q1 2025. Aardvark held $91.2 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into mid-2027.